TrialScientific reports2023

A Phase 3, randomized, non-inferiority study of a heterologous booster dose of SARS CoV-2 recombinant spike protein vaccine in adults.

Prasad S Kulkarni et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.